The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

The following is a summary of “Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the ...

Gilead is a dominant player in the HIV market. Biktarvy is the number one prescribed regimen for both treatment-naïve and switch patients. It continues to maintain its dominant position with an ...

Early diagnosis is vital for HIV. The sooner you receive a blood test and diagnosis, the sooner you can start treatment to bring and keep HIV at undetectable levels. Staying in close contact with ...

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...